Blue Sky Biotech Announces New Investment with Ampersand Ventures Blue Sky is thrilled with the partnership with Ampersand. This event forges together two successful entities with shared objectives toward strategic expansion, superior customer service, value-added technology platforms, and industry-leading cycle times.

Blue Sky announced the appointment of Dr. Kelvin Lam as Vice President, Assay Services. Dr. Lam joins Blue Sky with more than 18 years of experience in High Throughput Screening (HTS) and High Content Screening (HCS) of small molecule and natural products. He previously served as Director of HTS at Harvard Stem Cell Institute (HSCI), Harvard University, providing assay development and image-based screening services to Principle Investigators affiliated with HSCI and the Department of Stem Cell and Regenerative Biology (SCRB). In addition to his accomplishments at Harvard, Dr. Lam has an impressive track record of successfully implementing HTS/HCS and related technologies at Pfizer and Scriptgen Pharmaceuticals.